Meeting Banner
Abstract #3844

Deferiprone has a dose-dependent effect on liver iron concentration assessed by MRI

Antonella Meloni1, Vincenzo Positano1, Gianluca Valeri2, Gennaro Restaino3, Chiara Tudisca4, Paolo Preziosi5, Elisabetta Chiodi6, Maria Giovanna Neri1, Stefano Pulini7, Basilia Piraino8, Petra Keilberg1, and Alessia Pepe1

1Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, 2Azienda Ospedaliero-Universitaria Ospedali Riuniti "Umberto I-Lancisi-Salesi", Ancona, Italy, 3Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy, 4Policlinico "Paolo Giaccone", Palermo, Italy, 5Policlinico “Casilino", Roma, Italy, 6Arcispedale “S. Anna”, Ferrara, Italy, 7Ospedale Civile “Spirito Santo”, Pescara, Italy, 8Policlinico "G. Martino", Messina, Italy

The aim of this multi-centre study was to retrospectively assess in thalassemia major (TM) if deferiprone (DFP) had a dose-dependent effect on liver iron concentration (LIC) assessed by quantitative magnetic resonance imaging (MRI). We found out that the percentage of patients that worsened their status was significantly higher in patients with ≤ 75 mg/kg/d than in patients with > 75 mg/kg/d (26.6% vs 7.7%; P=0.016). So, the worsening in MRI LIC can be prevented by increasing the dose of deferiprone above the widely used regimen of 75 mg/kg body weight.

This abstract and the presentation materials are available to members only; a login is required.

Join Here